Background: Intermittent infusion hemodiafiltration -(I-HDF) using repeated infusion of ultrapure dialysis fluid through a dialysis membrane or sterile nonpyrogenic substitution fluid was developed to prevent a rapid decrease in blood pressure by increasing the patient’s circulating blood volume, to enhance the plasma refilling rate by improving peripheral circulation, and to enhance solute transfer from the extravascular space to the intravascular space by enhancing the plasma refilling rate. Furthermore, the effect of fouling caused by attachment of proteins to the membrane as a result of ultrafiltration can be reduced by backflushing of the membrane with the purified dialysate in I-HDF. Although there have been several clinical trials of I-HDF, there have been no comparisons of the clinical significance of and indications for -I-HDF with those of conventional hemodialysis (HD). Objective: The aim of this multicenter randomized controlled crossover trial was to compare the clinical significance of -I-HDF with that of HD in Japan. Method: Patients were randomized to receive HD, I-HDF, and HD (group A) or I-HDF, HD, and I-HDF (group B) in that order for 14 weeks each. The sample size of 70 was determined based on the operability and patient availability. Treatment outcomes were evaluated 5 and 14 weeks after the start of each treatment period. The patients received 4-h treatment sessions with no changes in session duration or anticoagulant therapy during the study. I-HDF was performed using a GC-110N dialysis machine. Two hundred milliliters of ultrapure dialysis fluid were infused at a rate of 150 mL/min by backfiltration every 30 min during treatment. The first and last infusions were performed 30 min after the start and 30 min before the end of treatment, respectively. The total estimated infusion volume per session was 1.4 L (i.e., 200 mL × 7 infusions). I-HDF is a type of online HDF with a small fluid replacement volume. An ABH-P polysulfone membrane hemodiafilter was used for -I-HDF and a class 1 or 2 hemodialyzer with a polysulfone membrane not coated with vitamin E and approved by the Japanese reimbursement system was used for HD. The primary outcomes were the Short Form-36 version 2 summary scores for quality of life and the visual analog scale scores for clinical symptoms. Secondary outcomes were vital signs, number of interventions, and pre-treatment blood test results. These variables were evaluated 1 week before at the start of the study, and at 5 and 14 weeks after the start of each treatment period. The removal characteristics of the various solutes were evaluated when possible on the first day of each treatment period. All patients provided written informed consent to participate. Results: Thirty-two patients in group A and 32 patients in group B completed the trial. There were no differences in the primary or secondary outcomes between I-HDF and HD. Serum α1-microglobulin (MG) levels at 14 weeks were significantly lower for I-HDF than for HD. During treatment, the removal rates for urea and creatinine, which are low molecular weight substances, were significantly lower during I-HDF than during HD. In contrast, the β2-MG and α1-MG removal rates were significantly higher during I-HDF than during HD. Furthermore, there was significantly less albumin leak during I-HDF than during HD. The solute removal results reflect the difference in pore size between the hemodiafilter used for I-HDF and the hemodialyzer used for HD and the difference in convective transport attributable to filtration between the 2 methods. Conclusions: These findings show that the removal rates of low molecular weight substances are significantly lower and those of medium to high molecular weight substances are significantly higher with I-HDF than with HD. They also indicate that there is significantly less albumin leak during I-HDF than during HD, meaning that I-HDF may be a particularly suitable dialysis modality for patients with malnutrition and the elderly in Japan.

1.
Eguchi K, Ikebe M, Konno Y, Yamada Y, Kaneko K, Mineshima M, et al. Development and clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF) as a new therapy.
J of Jap Soc Dialy Ther
. 2007;40(9):769–74.
2.
Eguchi K, Masaki M, Yamada Y, Konno Y, Kaneko I, Mineshima M, et al. Clinical assessment of intermittent infusion dialysis (I-HD) using backfiltration of ultrapure dialysis fluid by an automated machine.
J of Jap Soc Dialy Ther
. 2009;42(9):695–703.
3.
Mineshima M, Eguchi K. Development of intermittent infusion hemodiafiltration using ultrapure dialysis fluid with an automated dialysis machine.
Blood Purif
. 2013;35(suppl 1):55–8.
4.
Miyazaki M, Fukuda M, Uezumi S, Yoshida H, Takahashi T, Watanabe T, et al. Effect of operating conditions on solute removal amount during a Hemodialysis using several hemodialyzers with enhanced internal filtration and automated dialysis console produced by JMS.
Kidney and Dialysis, High Performance Membrane
. 2006;61:126–32.
5.
Mineshima M, Eguchi K, Shishido K, Takahashi S, Kubo T, Kawaguchi H, et al. Clinical effectiveness of intermittent infusion hemodiafiltration using backfiltration of ultrapure dialysis fluid compared with predilution online hemodiafiltration; a prospective, multicenter and controlled trial.
J of Jap Soc Dialy Ther
. 2015;48(6):351–60.
6.
Mineshima M, Eguchi K, Shishido K, Takahashi S, Kubo T, Kawaguchi H, et al. Clinical effectiveness of Intermittent Infusion Hemodiafiltration using backfiltration of ultrapure dialysis fluid compared with Predilution On-line Hemodiafiltration. In: Kawanishi H, Takemoto Y, editors.
Scientific Aspects of Dialysis Therapy, JSDT/JSFA Anniversary Edition, Contrib to Nephrol
. Volume 189. Basel: Karger; 2017. pp. 24–9.
7.
Koda Y, Aoike I, Hasegawa S, Osawa Y, Nakagawa Y, Iwabuchi F, et al. Feasibility of intermittent back-filtrate infusion hemodiafiltration to reduce intradialytic hypotension in patients with cardiovascular instability: a pilot study.
Clin Exp Nephrol
. 2017 Apr;21(2):324–32.
8.
Cogan MG, Garovoy MR.
Introduction to Dialysis
. New York: Churchll Living-Stone; 1985.
9.
Masakane I. Selection of dilutional method for on-line HDF, pre- or post-dilution.
Blood Purif
. 2004;22(suppl 2):49–54.
10.
Mineshima M, Ishimori I, Sakiyama R. Validity of internal filtration-enhanced hemodialysis as a new hemodiafiltration therapy.
Blood Purif
. 2009;27(1):33–7.
11.
Mineshima M, Abe T, Kamei D. Evaluation of the time-averaged solute clearance values in Hemodialysis with Intermittent Infusion (I-HD).
ASAIO J
. 2018;64(suppl 1):131.
12.
Saito A, Chung TG, Kanazawa I, Ogawa H, Ohta K. Middle and large molecule removal of protein-permeating hemodiafiltration. In: Piskin E, Chang TMS, editors. Proc 4th Int Symp Hemoperfusion Artif Organs. Ankara: Turkish Artif Organs Soc; 1982, pp. 42-46.
13.
Saito A, Ogawa H, Takagi T, Ohta K, Akasu H, Kawai S, et al. A new approach to glomerular filtration.
Trans Am Soc Artif Intern Organs
. 1983;29:673–7.
14.
Tsuchida K, Minakuchi J. Albumin loss under the use of the high-performance membrane. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-Performance Membrane Dialyzers. Contrib to Nephrol. Basel: Karger; 2011, Vol 173, pp. 76–83.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.